Clinical trials: Oral Disorder
Pulmonary Disease, Chronic Obstructive
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
This clinical study was designed to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in Chronic obstructive pulmonary disease (COPD) patients with chronic bronchitis and a…
- Trial name
- NCT04072887
- Testing
- QBW251, COPD maintenance background therapy
- Where
- 148 sites in United States, Argentina and 24 more
- Volunteers
- 974 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus
This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.
- Trial name
- NCT02445911
- Testing
- KQ-791
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Kaneq Bioscience Limited
Adenocarcinoma, Pancreatic Neoplasms
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
This study is to evaluate the combination of an investigational drug X-82 with everolimus in the treatment of pancreatic neuroendocrine tumors.
- Trial name
- NCT01784861
- Testing
- X-82, Everolimus
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Washington University School of Medicine
Graft Versus Host Disease, Hematologic Malignancies
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
The main purpose of this study is to evaluate the effect of palifermin versus placebo in the reduction of severe acute graft versus host disease (GVHD) and severe oral mucositis.
- Trial name
- NCT00189488
- Testing
- Palifermin, Conditioning Regimen, Allogeneic stem cell transplant
- Volunteers
- 155 people
- Sponsor
- Swedish Orphan Biovitrum
Iron Deficiency Anemia
Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia
The aim of the study is to recruit 30 patients who have been referred to Auerach Hematology Oncology Assoc. for the treatment of iron defeciency anemia with iv iron (Ferumoxytol 1020 mg) administered via infusion pump over 15…
- Trial name
- NCT01374919
- Testing
- ferumoxytol
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Auerbach Hematology Oncology Associates P C
Aggressive Periodontitis
Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis
The aim of this study is to assess the clinical outcomes of full-mouth ultrasonic debridement combined with clarithromycin or amoxicillin + metronidazole association for the treatment of generalized aggressive periodontitis…
- Trial name
- NCT02969928
- Testing
- Full-mouth ultrasonic debridement, Clarithromycin, Amoxicillin
- Where
- Brazil
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
Parkinson Disease
Pivotal Study in Advanced Parkinsons Disease Patients
The general aim of this trial is to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for Unified Parkinsons Disease Rating Scale Parts II and III combined)…
- Trial name
- NCT00466167
- Testing
- Pramipexol Extended Release, Pramipexol Immediate Release
- Where
- 76 sites in Austria, Czechia and 12 more
- Volunteers
- 517 people
- Sponsor
- Boehringer Ingelheim
Diabetes Type 2
Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Randomized, double-blind, placebo-controlled, parallel group study.
- Trial name
- NCT02496000
- Testing
- ORMD-0801
- Where
- 34 sites in United States
- Volunteers
- 188 people
- Sponsor
- Oramed, Ltd.
Leukemia
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
The purpose of this study was to determine the efficacy and safety of twice daily (bid) oral midostaurin in patients with Aggressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia (MCL) with or without an Associated…
- Trial name
- NCT00782067
- Testing
- Midostaurin (PKC412)
- Where
- 29 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
This is a phase I/II pediatric dose-ranging study that will evaluate the safety, tolerability, clinical response, pharmacokinetics and pharmacodynamics of midostaurin in patients <18 years of age who have relapsed or refractory…
- Trial name
- NCT00866281
- Testing
- midostaurin
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Food Allergy
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
- Trial name
- NCT04856865
- Testing
- Low dose ADP101, High dose ADP101
- Where
- 15 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
Diabetes, Diabetes Mellitus, Type 2
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the dose-response relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide versus placebo as monotherapy on glycaemic…
- Trial name
- PIONEER 9 (NCT03018028)
- Testing
- Semaglutide, Liraglutide
- Where
- 16 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Novo Nordisk A/S
Solid Tumors, Non-small Cell Lung Carcinoma
A Study of DS-2248 in Participants With Advanced Solid Tumors
This phase 1 clinical trial is intended to understand the safety and tolerability of a new anticancer drug in subjects with advanced solid tumors.
- Trial name
- NCT01288430
- Testing
- DS-2248
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Daiichi Sankyo
Methamphetamine Use Disorder
Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM
This is a double-blind, placebo-controlled phase 2b trial in which 54 MSM who use meth will be randomly assigned (2:1) to receive 12 weeks of as-needed intermittent oral naltrexone 50 mg enhanced with an EMA-informed EMI…
- Trial name
- NCT04791969
- Testing
- Naltrexone Hydrochloride, Ecological Momentary Intervention
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Glenn-Milo Santos
Pulmonary Fibrosis
Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis
The general purpose of this trial is to investigate the efficacy and safety of 4 dose strategies of BIBF 1120 treatment for 12 months, compared to placebo in patients with idiopathic pulmonary fibrosis.
- Trial name
- NCT00514683
- Testing
- low dose BIBF1120 once daily, low dose BIBF 1120 twice daily, intermediate dose BIBF 1120 twice daily
- Where
- 92 sites in Argentina, Australia and 23 more
- Volunteers
- 432 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX3305 versus a placebo control in subjects with active rheumatoid arthritis on stable methotrexate therapy.
- Trial name
- NCT00903383
- Testing
- LX3305 low dose, LX3305 mid dose, LX3305 high dose
- Where
- 38 sites in United States, Bulgaria and 4 more
- Volunteers
- 208 people
- Sponsor
- Lexicon Pharmaceuticals
Neoplasms, Breast
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
The purpose of this study is to determine the efficacy and safety of an oral dual tyrosine kinase inhibitor (GW572016) in combination with paclitaxel compared to paclitaxel alone in first line advanced or metastatic breast cancer.
- Trial name
- NCT00075270
- Testing
- Paclitaxel, GW572016 (Lapatinib)
- Where
- 177 sites in United States, Argentina and 23 more
- Volunteers
- 580 people
- Sponsor
- GlaxoSmithKline
Urinary Tract Infections
Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.
This is a phase 1, 2-part, double-blind (sponsor-unblinded), randomized, placebo-controlled, first time in human (FTIH) study, that includes both single-ascending and multiple-ascending dose phase to assess the safety…
- Trial name
- NCT04488770
- Testing
- GSK3882347
- Where
- United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dental Plaque
Evaluating the Effect of Tooth Cleaning Devices on Oral Health
This is a study to evaluate the safety and the efficacy of tooth and interproximal cleaning modalities on oral health.
- Trial name
- NCT01250769
- Testing
- Manual Toothbrush, Interproximal Cleaning Device
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Philips Oral Healthcare
Spinal Cord Injury
Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage
The annual incidence of colorectal cancer in the US during 2005 was approximately 150,000 cases and this neoplasm claimed 56,000 lives (American Cancer Society).
- Trial name
- NCT00745095
- Testing
- Neostigmine
- Where
- United States
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.